ZBIO (Zenas BioPharma) EPS (Basic): $-8.47 (TTM As of Mar. 2026)


ZBIO Zenas BioPharma Inc ZBIO
12 GF Score
Price $24.78
! 1 Warning Sign
View Full Analysis

What is Zenas BioPharma EPS (Basic)?

Zenas BioPharma ZBIO +13.67% 12 EPS (Basic) is $-8.47 as of Mar. 2026. GuruFocus rates ZBIO with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Zenas BioPharma's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was $-1.46. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was $-8.47.

Zenas BioPharma's EPS (Diluted) for the three months ended in Mar. 2026 was $-1.46. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-8.47.

Zenas BioPharma's EPS without NRI for the three months ended in Mar. 2026 was $-1.46. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -5.87.

During the past 3 years, the average EPS without NRI Growth Rate was 7.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 4 years, Zenas BioPharma's highest 3-Year average EPS without NRI Growth Rate was 7.60% per year. The lowest was 7.60% per year. And the median was 7.60% per year.

Zenas BioPharma  (NAS:ZBIO) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Zenas BioPharma EPS (Basic) Related Terms

Zenas BioPharma EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Zenas BioPharma's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zenas BioPharma EPS (Basic) Chart

Zenas BioPharma Annual Data
Trend Dec22 Dec23 Dec24 Dec25
EPS (Basic)
-9.26 -2.13 -11.89 -8.44

Zenas BioPharma Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.80 -1.25 -1.22 -4.54 -1.46
ZBIO
12GF Score
Zenas BioPharma Inc ZBIO
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zenas BioPharma EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Zenas BioPharma's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-377.737-0)/44.730
=-8.44

Zenas BioPharma's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-80.987-0)/55.625
=-1.46

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $-8.47 mean?
Zenas BioPharma (ZBIO) has a EPS (Basic) of $-8.47 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Zenas BioPharma and its competitors.
Is Zenas BioPharma's EPS (Basic) too high?
Zenas BioPharma's current EPS (Basic) is $-8.47. Overall, Zenas BioPharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Zenas BioPharma's EPS (Basic) compare to MNKD and OLMA?
Zenas BioPharma's EPS (Basic) of $-8.47 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Zenas BioPharma and its competitors. Zenas BioPharma's current EPS (Basic) is $-8.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenas BioPharma stock overvalued right now?
Zenas BioPharma (ZBIO) has a current EPS (Basic) of $-8.47. The current EPS (Basic) is $-8.47. Zenas BioPharma's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Zenas BioPharma (ZBIO), the current EPS (Basic) is $-8.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zenas BioPharma Business Description

Address 852 Winter Street, Suite 250, Waltham, MA, USA, 02451
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
12GF Score

Get the complete analysis for ZBIO

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.78
Price